News zum Sektor Gesundheit aus Neuseeland

 

Royalties rise at Neuren, but total income falls for FY25. The post Neuren shares dip after FY25 result. Here's what stood out appeared first on The Motley Fool Australia....

Neuren saw 2025 DAYBUE royalties jump 15% to $65 million, with profit after tax reaching $30 million and a new buy-back announced. The post Neuren Pharmaceuticals earnings: Profits up, pipeline builds in 2025 appeared first on The Motley Fool Australia....

Summerset Group delivered record underlying profit and strong sales in FY25, boosting confidence for the year ahead. The post Summerset Group reports record FY25 profit and strong sales appeared first on The Motley Fool Australia....

Neuren shares jump after an updated DAYBUE sales outlook. The post Why Neuren shares are jumping more than 6% today appeared first on The Motley Fool Australia....

Trading in Neuren Pharmaceuticals shares is paused as investors await a further announcement from the company. The post Neuren Pharmaceuticals shares paused ahead of company announcement appeared first on The Motley Fool Australia....

Fisher & Paykel Healthcare has raised its FY26 revenue and profit guidance, with tariff updates on the horizon. The post Fisher & Paykel Healthcare upgrades FY26 earnings outlook appeared first on The Motley Fool Australia....

A leading fund manager believes the sell-down in Xero, TechnologyOne, and Pro Medicus shares has been overdone. The post Why this top fundie is doubling down on ASX 200 tech stocks like TechnologyOne and Xero shares appeared first on The Motley Fool Australia....

Neuren shares slip despite management announcing a new buyback program. The post Why Neuren shares are edging lower on Thursday appeared first on The Motley Fool Australia....

Neuren Pharmaceuticals launches new share buy-back program on the back of growing revenue and drug development progress. The post Neuren Pharmaceuticals unveils on-market buy-back supported by strong cash flows appeared first on The Motley Fool Australia....

Find insight on Bayer, Mega Lifesciences and Neuren Pharmaceuticals in the latest Market Talks covering Health Care....

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome. The post Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome appeared first on The Motley Fool Australia....

These shares are under pressure on Thursday. But why? The post Why Beach Energy, Elders, Maas, and Neuren shares are dropping today appeared first on The Motley Fool Australia....

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. The post Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs appeared first on The Motley Fool Australia....

With more than seven million users on the HotCopper forums, every discussion and speculation…...

Neuren Pharmaceuticals shares are paused from trading as investors await a further announcement from the company. The post Neuren Pharmaceuticals shares paused pending announcement appeared first on The Motley Fool Australia....

These shares are missing out on the good times on Tuesday. But why? The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia....

With more than seven million users on the HotCopper forums, every discussion and speculation…...

Company fueled by strong 2025 customer momentumAUSTIN, Texas--(BUSINESS WIRE)--Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced strong 2025 momentum, driven by significant customer growth, AI innovation, and industry recognition throughout the year. Additionally, Planview enters 2026 with new CEO Matt Zilli at the helm and an updated leadership team to accelerate its AI-first strategy. New Logo and Customer Momentum in 2025 Key customer wins and expansions across Financial Services, Insurance, Healthcare, Technology, Retail, and more have driven Planview's continued profitable growth. In 2025, the company added 274 net new customers; notable customers who selected or expanded their footprint with Planview in 2025 included: Currys Group, DHL, DTCC, EDF Renewables, Farmacia Guadalajara, Fisher & Paykel Healthcare, FIS, Garrett Motion, General Mills, Getinge Sterilization, Global Payments, Harman Connected Services, HCSC, Huntin...

Summerset Group reported record FY25 retirement village sales, up 26%, with strong growth in New Zealand and Australia. The post Summerset Group Holdings FY25 results: record sales and growth momentum appeared first on The Motley Fool Australia....

Neuren Pharmaceuticals has projected DAYBUE global net sales to hit US$700 million by 2028. The post Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028 appeared first on The Motley Fool Australia....